Company intelligence / Profile preview
Amyl Therapeutics
Liège, Belgiumamyltx.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
The company is developing novel molecules that conformationally bind to the amyloid fold of toxic protein aggregates. Their lead candidate is expected to begin Phase I trials in 2025 for amyloidosis, with preclinical studies ending in the coming months. The company claims its technology can target all amyloid fibrils, offering an advantage over classical monoclonal antibodies.
- Therapeutic areas
- HematologyNeurology
- Modalities
- Pan-Amyloid Immunotherapy
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
Beyond the preview
Go deeper on Amyl Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amyl Therapeutics.